Liraglutide
FDA-approved drugAlso known as: 204656-20-2, NN2211, Liraglutida, Liraglutidum, Saxenda, victoza, NN-2211, Liraglutide recombinant
Liraglutide (204656-20-2, NN2211, Liraglutida) is classified under glp-1 & incretin agonists, an FDA-approved drug.
Read the full guide: what the research shows on Liraglutide →What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
Liraglutide (GLP-1 receptor agonist; aliases include Saxenda and Victoza) has been studied for weight loss and for various metabolic-related conditions. A systematic review of randomized controlled trials in adults without diabetes reported weight-loss effects compared with placebo, with gastrointestinal adverse events being the predominant safety concern.
Mechanism (as reported)
A class review reported that GLP-1 receptor agonists share mechanisms including augmentation of glucose-stimulated insulin secretion, suppression of glucagon secretion (at hyper- or euglycemia), deceleration of gastric emptying, and reduction in calorie intake and body weight. (PMID: 33068776) A connectomics study reported that liraglutide activated GLP-1 receptor–expressing inhibitory neurons (TRHArc neurons) that inhibited hunger-promoting AgRP neurons in a mouse satiety circuit, affecting feeding and weight-related effects. (PMID: 39627618)
Key findings (each cites a source)
- A systematic review of randomized controlled trials in adults without diabetes (26 RCTs; 15,491 participants) reported that liraglutide produced weight loss of up to 5.8% (95% CI 3.6% to 8.0%) after 26 weeks compared with placebo. [PMID 39761578]
- In the same systematic review, gastrointestinal adverse events were reported as the most common adverse events for GLP-1 receptor agonists, and serious adverse events and adverse events requiring discontinuation were rare. [PMID 39761578]
- A review of GLP-1 receptor agonists in type 2 diabetes described shared mechanisms including augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying, and reduction in calorie intake and body weight. [PMID 33068776]
- A mouse connectomics study reported that liraglutide activated TRH+ Arc neurons predicted to express the Glp1r gene and that activating these neurons inhibited AgRP neurons and feeding; silencing TRHArc neurons reportedly caused overeating/weight gain and attenuated liraglutide's effect on body weight. [PMID 39627618]
- A pharmacovigilance analysis of individual case safety reports in EudraVigilance (01/01/2021–30/05/2023) identified psychiatric adverse event reports for liraglutide and found depression as the most commonly reported psychiatric adverse event; the analysis also reported deaths and life-threatening outcomes in association with some reports (including liraglutide). [PMID 38265519]
Independent test grades
No independent third-party test data is available for Liraglutide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (10)
Consolidated from PubMed — each links to the original record.
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM · Annals of internal medicine · 2025 · PMID 39761578
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
Tobaiqy M, Elkout H · International journal of clinical pharmacy · 2024 · PMID 38265519
- Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
Dubin RL, Heymsfield SB, Ravussin E, Greenway FL · Diabetes, obesity & metabolism · 2024 · PMID 39344838
- Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety.
Webster AN, Becker JJ, Li C, Schwalbe DC, Kerspern D, Karolczak EO · Nature metabolism · 2024 · PMID 39627618
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.
Singh A, Sohal A, Batta A · World journal of gastroenterology · 2024 · PMID 39735270
- Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE (-/-) mice.
Zhang K, Li R, Matniyaz Y, Yu R, Pan J, Liu W · Biochemical pharmacology · 2024 · PMID 38548245
FAQ
- What is Liraglutide?
- Liraglutide (204656-20-2, NN2211, Liraglutida) is classified under glp-1 & incretin agonists, an FDA-approved drug. Research goals associated with it include metabolic & weight.
- Is Liraglutide FDA-approved?
- Yes — Liraglutide is approved by the FDA (marketed as 204656-20-2, NN2211).
- What does the research on Liraglutide say?
- peptideone aggregates 10 references from PubMed for Liraglutide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.